CM
MRNS

Caption Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Caption Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-378,400
Closed -$3.42M – 1600
2024
Q1 		$3.42M Buy
+378,400
New +$3.68M 0.05% 394
2021
Q1 		– Sell
-74,300
Closed -$907K – 1467
2020
Q4 		$907K Buy
74,300
+100
+0.1% +$1.39K 0.02% 630
2020
Q3 		$953K Buy
74,200
+54,575
+278% +$471K 0.02% 630
2020
Q2 		$199K Sell
19,625
-725
-4% -$6.67K 0.01% 794
2020
Q1 		$166K Hold
20,350
– – 0.01% 720
2019
Q4 		$175K Hold
20,350
– – 0.01% 732
2019
Q3 		$125K Sell
20,350
-78,450
-79% -$634K 0.01% 627
2019
Q2 		$1.64M Buy
98,800
+36,300
+58% +$630K 0.08% 287
2019
Q1 		$1.04M Buy
62,500
+56,175
+888% +$809K 0.06% 345
2018
Q4 		$73K Buy
+6,325
New +$128K 0.01% 431

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Caption Management's MRNS Position: Q3 2024 in Review

Caption Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2024, closing a stake of 200 shares — an estimated $234 sold.

Caption Management first reported a position in MRNS in Q3 2018 and held it in 16 quarters. The position peaked at $1.89M in Q3 2018. 75 funds tracked by Wall St. Rank hold MRNS as of Q3 2024.

  • Caption Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2024 after selling out during the quarter.
  • Caption Management sold 200 Marinus Pharmaceuticals, Inc shares in Q3 2024, an estimated $234.
  • Caption Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2018 and held it in 16 quarters.
  • Caption Management's Marinus Pharmaceuticals, Inc position peaked at $1.89M in Q3 2018.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2024.

Based on Caption Management's 13F filing for Q3 2024, filed 14 Nov 2024.